Literature DB >> 27225621

Outcome and CT differentiation of gallbladder neuroendocrine tumours from adenocarcinomas.

Tae-Hyung Kim1, Se Hyung Kim2,3,4, Kyoung Boon Lee5, Joon Koo Han1,6,7.   

Abstract

OBJECTIVES: To retrospectively investigate clinical outcome and differential CT features of gallbladder (GB) neuroendocrine tumours (NETs) from adenocarcinomas (ADCs).
MATERIALS AND METHODS: Nineteen patients with poorly-differentiated (PD) NETs and 19 patients with PD ADCs were enrolled. Clinical outcome was compared by the Kaplan-Meier method. We assessed qualitative and quantitative CT features to identify significant differential CT features of PD NETs from ADCs using univariate and multivariate analyses. Receiver operating characteristic (ROC) analysis was used for quantitative CT features.
RESULTS: PD NETs showed poorer prognosis with significantly shorter median survival days than ADCs (363 vs. 590 days, P = 0.03). On univariate analysis, NETs more frequently manifested as GB-replacing type and showed well-defined margins accompanied with intact overlying mucosa. On multivariate analysis, well-defined margin was the sole significant CT differentiator (odds ratio = 27.817, P = 0.045). Maximum size of hepatic and lymph node (LN) metastases was significantly larger in NETs (11.0 cm and 4.62 cm) than ADCs (2.40 cm and 2.41 cm). Areas under ROC curves for tumour-to-mucosa ratio, maximum size of hepatic and LN metastasis were 0.772, 0.932 and 0.919, respectively (P < 0.05).
CONCLUSION: GB PD NETs show poorer prognosis than ADCs. Well-defined margin, larger hepatic and LN metastases are useful CT differentiators of GB NETs from ADCs. KEY POINTS: • A well-defined margin is a useful CT differentiator of GB NETs from ADCs. • Hepatic and LN metastases are significantly larger in NETs than in ADCs. • Primary tumour and hepatic metastasis of NETs are more hyperattenuated than ADCs.

Entities:  

Keywords:  Adenocarcinomas; CT; Differentiation; Gallbladder; Neuroendocrine tumours

Mesh:

Year:  2016        PMID: 27225621     DOI: 10.1007/s00330-016-4394-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  21 in total

1.  Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.

Authors:  George C Nikou; N J Lygidakis; Christos Toubanakis; Spiridon Pavlatos; Sofia Tseleni-Balafouta; Eleanna Giannatou; Elias Mallas; Michael Safioleas
Journal:  Hepatogastroenterology       Date:  2005 May-Jun

2.  Primary neuroendocrine tumors of the gallbladder: Ultrasonographic and MDCT features with pathologic correlation.

Authors:  H El Fattach; Y Guerrache; C Eveno; M Pocard; R Kaci; C Shaar-Chneker; R Dautry; M Boudiaf; A Dohan; P Soyer
Journal:  Diagn Interv Imaging       Date:  2014-12-17       Impact factor: 4.026

Review 3.  An analysis of rare carcinoid tumors: clarifying these clinical conundrums.

Authors:  Irvin M Modlin; Michael D Shapiro; Mark Kidd
Journal:  World J Surg       Date:  2005-01       Impact factor: 3.352

4.  MDCT findings in neuroendocrine carcinoma of the gallbladder: case report.

Authors:  F Obuz; C Altay; O Sagol; H Astarcioglu; I Oztop; E Igci
Journal:  Abdom Imaging       Date:  2007 Jan-Feb

Review 5.  Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy.

Authors:  Karim M Eltawil; Bjorn I Gustafsson; Mark Kidd; Irvin M Modlin
Journal:  J Clin Gastroenterol       Date:  2010 Nov-Dec       Impact factor: 3.062

6.  Clinical outcomes of small cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder.

Authors:  Sung Pil Yun; Nari Shin; Hyung Il Seo
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 7.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 8.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

Authors:  Thomas J Vogl; Nagy N N Naguib; Stefan Zangos; Katrin Eichler; Alborz Hedayati; Nour-Eldin A Nour-Eldin
Journal:  Eur J Radiol       Date:  2008-10-01       Impact factor: 3.528

9.  Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma.

Authors:  Jung Hoon Kim; Hyo Won Eun; Young Jae Kim; Jeong Min Lee; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

10.  Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma.

Authors:  Chen Chen; Lin Wang; Xi Liu; Guanjun Zhang; Yaling Zhao; Zhimin Geng
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
View more
  8 in total

1.  Poorly-differentiated colorectal neuroendocrine tumour: CT differentiation from well-differentiated neuroendocrine tumour and poorly-differentiated adenocarcinomas.

Authors:  Ji Hee Kang; Se Hyung Kim; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

2.  Neuroendocrine Carcinoma of the Gallbladder.

Authors:  Daniel A Vidal Panduro; Elizabeth Zegarra Buitron; Omar J Cochella Tizon; Domingo A Morales Luna
Journal:  Cureus       Date:  2022-07-19

3.  Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma.

Authors:  Yong Cui; Zhong-Wu Li; Xiao-Ting Li; Shun-Yu Gao; Ying Li; Jie Li; Hui-Ci Zhu; Lei Tang; Kun Cao; Ying-Shi Sun
Journal:  Oncotarget       Date:  2017-11-20

4.  Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching.

Authors:  Shida Yan; Yingyi Wang; Xiao Chen; Yefan Zhang; Zhen Huang; Jianjun Zhao; Jianguo Zhou; Zhiyu Li; Xinyu Bi; Zhiwen Luo; Jianqiang Cai; Hong Zhao
Journal:  Cancer Manag Res       Date:  2020-02-26       Impact factor: 3.989

5.  Flushing as atypical initial presentation of functional gallbladder neuroendocrine carcinoma: A case report.

Authors:  Ming Jin; Bo Zhou; Xiong-Ling Jiang; Qi-Yi Zhang; Xiang Zheng; Yuan-Cong Jiang; Sheng Yan
Journal:  World J Gastroenterol       Date:  2020-02-14       Impact factor: 5.742

Review 6.  Imaging-based algorithmic approach to gallbladder wall thickening.

Authors:  Pankaj Gupta; Yashi Marodia; Akash Bansal; Naveen Kalra; Praveen Kumar-M; Vishal Sharma; Usha Dutta; Manavjit Singh Sandhu
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

7.  Update in clinical management for gallbladder neuroendocrine carcinoma.

Authors:  Hongwu Chu; Ying Shi; Junwei Liu; Dongsheng Huang; Jungang Zhang; Changwei Dou
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

8.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.